Robert J. Feeney
Amministratore Delegato presso CS-Keys, Inc.
Profilo
Robert J.
Feeney is currently the President & Chief Executive Officer at CS-Keys, Inc. He previously worked as a Director at Cephalon, Inc., Director-Marketing, Scientific & Clinical Affairs at US Pathology Labs, Inc., Associate Marketing Manager at Eli Lilly & Co., Regional Sales Manager at IMPATH, Inc., and Vice President-Sales & Marketing at NeoGenomics, Inc. Feeney holds a doctorate degree from Stony Brook University and an undergraduate degree from Dickinson College.
Posizioni attive di Robert J. Feeney
Società | Posizione | Inizio |
---|---|---|
CS-Keys, Inc.
CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Amministratore Delegato | 11/05/2010 |
Precedenti posizioni note di Robert J. Feeney
Società | Posizione | Fine |
---|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Direttore/Membro del Consiglio | 18/05/2005 |
IMPATH, Inc. | Vendite & Marketing | - |
ELI LILLY AND COMPANY | Vendite & Marketing | - |
US Pathology Labs, Inc.
US Pathology Labs, Inc. Medical/Nursing ServicesHealth Services US Pathology Labs, Inc. operates anatomic pathology laboratories. The firm offers diagnosis, prognosis, genomics, and genetic testing services to hospitals, physician offices, surgery centers, and biopharmaceutical companies. The company was founded in 1997 and is headquartered in Irvine, CA. | Direttore Tecnico/Scientifico/R&S | - |
NEOGENOMICS, INC. | Vendite & Marketing | - |
Formazione di Robert J. Feeney
Dickinson College | Undergraduate Degree |
Stony Brook University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
NEOGENOMICS, INC. | Health Services |
ELI LILLY AND COMPANY | Health Technology |
Aziende private | 4 |
---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
US Pathology Labs, Inc.
US Pathology Labs, Inc. Medical/Nursing ServicesHealth Services US Pathology Labs, Inc. operates anatomic pathology laboratories. The firm offers diagnosis, prognosis, genomics, and genetic testing services to hospitals, physician offices, surgery centers, and biopharmaceutical companies. The company was founded in 1997 and is headquartered in Irvine, CA. | Health Services |
IMPATH, Inc. | Health Services |
CS-Keys, Inc.
CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Health Technology |
- Borsa valori
- Insiders
- Robert J. Feeney